Urs Weber, MD
@urswebermd.bsky.social
Proud 🇩🇪, grew up in 🇩🇪/🇨🇭/🇬🇧/🇪🇸, now living in 🇺🇸. Oncology fellow at CU. Views are my own.
Reposted by Urs Weber, MD
CU Cancer Center member Tejas Patil, MD, enrolled Jennifer Brown in a clinical trial of a new type of immunotherapy to treat her lung cancer that had spread to her bones, liver, and brain. Brown had a remarkable response to the treatment ⬇️
https://bit.ly/47PaslL
https://bit.ly/47PaslL
‘An Incredible Response': A Clinical Trial at the CU Cancer Center Successfully Treated Jennifer Brown's Stage IV Lung Cancer
A clinical trial at the CU Cancer Center successfully treated Jennifer Brown's stage IV lung cancer, shrinking her liver metastases by 50% within weeks.
news.cuanschutz.edu
November 13, 2025 at 1:20 AM
CU Cancer Center member Tejas Patil, MD, enrolled Jennifer Brown in a clinical trial of a new type of immunotherapy to treat her lung cancer that had spread to her bones, liver, and brain. Brown had a remarkable response to the treatment ⬇️
https://bit.ly/47PaslL
https://bit.ly/47PaslL
Medical Oncology Board Exam ✅
November 6, 2025 at 8:14 PM
Medical Oncology Board Exam ✅
Reposted by Urs Weber, MD
The Colorado Public Radio interview with Andrea Dukakis aired this week. Andrea had lost her daughter to a brain tumor and so cancer is something that has touched her and her family directly. www.cpr.org/2025/10/28/l...
He has the same disease as his patients. How a renowned lung cancer doctor is facing life and death
Dr. Ross Camidge hopes talking about his cancer can help to de-stigmatize terminal illness and demonstrate that a person with cancer can still be a productive member of society.
www.cpr.org
October 29, 2025 at 9:57 PM
The Colorado Public Radio interview with Andrea Dukakis aired this week. Andrea had lost her daughter to a brain tumor and so cancer is something that has touched her and her family directly. www.cpr.org/2025/10/28/l...
Reposted by Urs Weber, MD
Paul Bunn, MD, inaugural director, and @drcamidge.bsky.social, MD, PhD, director of thoracic oncology, both share what has changed during their time with the CU Cancer Center and what the next 40 years can bring ⬇️
October 29, 2025 at 10:51 PM
Paul Bunn, MD, inaugural director, and @drcamidge.bsky.social, MD, PhD, director of thoracic oncology, both share what has changed during their time with the CU Cancer Center and what the next 40 years can bring ⬇️
It was a pleasure attending and speaking at the 2025 Seattle Lung Cancer Conference. The 🫁 were truly front and center! @binaytara.bsky.social #SeattleLung25
October 11, 2025 at 10:53 PM
It was a pleasure attending and speaking at the 2025 Seattle Lung Cancer Conference. The 🫁 were truly front and center! @binaytara.bsky.social #SeattleLung25
Watching @drcamidge.bsky.social navigate this cruel twist of fate for the last few years has been nothing short of inspirational. Becoming a lung cancer patient himself has made him an even better clinician, researcher, and advocate. I’m very fortunate to be able to learn from him.
A EGFR-mutated advanced non-small cell lung cancer diagnosis has not stopped @drcamidge.bsky.social from continuing his lung cancer research, training the next generation of lung cancer providers, and spending time with his family. https://bit.ly/47yGdBb
#LungCancer #LungCancerFighter
#LungCancer #LungCancerFighter
World Lung Cancer Expert Diagnosed with Advanced Lung Cancer
D. Ross Camidge, MD, PhD, has spent his career fighting lung cancer. In 2022, that fight turned personal when he received a diagnosis of his own.
news.cuanschutz.edu
September 8, 2025 at 5:56 PM
Watching @drcamidge.bsky.social navigate this cruel twist of fate for the last few years has been nothing short of inspirational. Becoming a lung cancer patient himself has made him an even better clinician, researcher, and advocate. I’m very fortunate to be able to learn from him.
Last day of clinic at the VA. It’s been an honor taking care of the veterans here for the last 2.5 years. I’ll miss my patients and the team in the hematology/oncology clinic.
June 25, 2025 at 6:54 PM
Last day of clinic at the VA. It’s been an honor taking care of the veterans here for the last 2.5 years. I’ll miss my patients and the team in the hematology/oncology clinic.
It’s getting real! I’m honored to soon be sharing an office with my mentor at @cucancercenter.bsky.social
June 20, 2025 at 11:04 PM
It’s getting real! I’m honored to soon be sharing an office with my mentor at @cucancercenter.bsky.social
Tarlatamab is clearly the best 2nd line therapy for small cell lung cancer available now. I’m excited to see this and similar agents develop and perhaps move into the 1st line. #ASCO2025
DeLLphi-304: Among patients with relapsed small-cell lung cancer after the failure of platinum-based chemotherapy, tarlatamab therapy led to a greater overall and progression-free survival benefit over chemotherapy, with fewer severe adverse events. nej.md/3YWiy8O
#ASCO25
#ASCO25
June 2, 2025 at 1:53 PM
Tarlatamab is clearly the best 2nd line therapy for small cell lung cancer available now. I’m excited to see this and similar agents develop and perhaps move into the 1st line. #ASCO2025
Neoadjuvant treatment with chemo-immunotherapy is clearly the new standard of care for most patients with resectable non-small cell lung cancer. The question remains what (if any) is the best adjuvant therapy for these patients? #ASCO2025
In non–small-cell lung cancer, three cycles of neoadjuvant nivolumab plus chemotherapy improved 5-year overall survival over chemotherapy alone, with variation according to pathological response. Full CheckMate 816 phase 3 trial results: nej.md/4k6Wlxj
#ASCO25 @ascocancer.bsky.social
#ASCO25 @ascocancer.bsky.social
June 2, 2025 at 1:49 PM
Neoadjuvant treatment with chemo-immunotherapy is clearly the new standard of care for most patients with resectable non-small cell lung cancer. The question remains what (if any) is the best adjuvant therapy for these patients? #ASCO2025
Exercise reduces the risk of cancer recurrence and improves survival after colon cancer treatment. I suspect that this is also true in other cancers. This should be one of the most impactful trials to come out of #ASCO2025!
Late breaking at #ASCO25:
A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial: nej.md/4mh5RPL
@ascocancer.bsky.social
A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial: nej.md/4mh5RPL
@ascocancer.bsky.social
June 1, 2025 at 7:51 PM
Exercise reduces the risk of cancer recurrence and improves survival after colon cancer treatment. I suspect that this is also true in other cancers. This should be one of the most impactful trials to come out of #ASCO2025!
I applaud these authors for trying to answer a very tricky question. I don’t quite know what to make of their numbers given the many unknowns and confounders, but I do believe that CTs increase cancer risk and that we could (and probably should) do less of them.
Projected Lifetime Cancer Risks From Current Computed Tomography Imaging
This risk model projects how many future cancers in the United States could result from annual computed tomography examinations.
jamanetwork.com
April 25, 2025 at 8:18 PM
I applaud these authors for trying to answer a very tricky question. I don’t quite know what to make of their numbers given the many unknowns and confounders, but I do believe that CTs increase cancer risk and that we could (and probably should) do less of them.
@drcamidge.bsky.social have you ever encountered central necrosis in your time in the oncologist’s garden?
April 24, 2025 at 4:58 PM
@drcamidge.bsky.social have you ever encountered central necrosis in your time in the oncologist’s garden?